United Therapeutics Co. Logo
US91307C1027
923818
UTHR

United Therapeutics Co.

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 610,15 € (+13,58 %). Medianen er 638,56 € (+18,87 %).

Køb
  18
Behold
  12
Sælg
  1

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Liquidia ends patent dispute with United Therapeutics – marketing of YUTREPIA secured

    Liquidia Technologies reached a global settlement in the patent dispute with United Therapeutics, clearing the legal path for marketing YUTREPIA to treat pulmonary arterial hypertension. After the settlement, the stock rose nearly 27% on October 14 to $33.94. In Q3 2026, Liquidia reported preliminary product revenues of $222.7 million and continues to benefit from its PRINT technology. » Mere på finanzen.net


  • United Therapeutics: patent win against Liquidia strengthens outlook despite appeal

    United Therapeutics won a preliminary patent ruling against Liquidia, which would ease competition for the PH-ILD indication in favor of Tyvaso. Liquidia plans to appeal, so the ruling is not yet final. Competitor Liquidia had rapidly gained market share with Yutrepia since June 2025 and generated $170.4 million in Q2, while Tyvaso sales fell 4% to $452.6 million. The patent victory is seen as an important step toward paving the way to a $1,000 price target for United Therapeutics. » Mere på finanzen.net


  • United Therapeutics bets on pulmonary fibrosis as new growth chapter

    At the Morgan Stanley Healthcare Conference United Therapeutics announced a strategic shift from a pulmonary hypertension specialist to a leading pulmonary fibrosis provider. Management highlighted positive Phase‑III data, an FDA review for nebulized Tyvaso in idiopathic pulmonary fibrosis with an expected launch in mid‑2025, and a near‑term sales target of $8 billion, while seeing a long‑term pharma opportunity of $40–100 billion. The company is simultaneously expanding sales, commercial infrastructure and a broader Tyvaso portfolio (DPI, Soft‑Mist); the stock then rose slightly to $502.70. » Mere på de.investing.com


  • United Therapeutics shifts focus to pulmonary fibrosis and launches $500 million share buyback

    United Therapeutics announced at the Cantor Fitzgerald Healthcare Conference a strategic shift from pulmonary hypertension to pulmonary fibrosis, supported by strong TETON-1/2 data for nebulized Tyvaso. The FDA has accepted the NDA; the PDUFA date is April 26, 2027, and Phase III data for progressive pulmonary fibrosis are expected in H2 2027. The company plans 14 product launches between 2027 and 2029, is expanding its sales force, and announced an accelerated $500 million share repurchase, but faces regulatory scrutiny, trial risks, and commercial execution challenges. » Mere på de.investing.com


  • United Therapeutics outlines pipeline plan for multibillion-dollar sales and boosts share buybacks

    At the Wells Fargo Healthcare Conference, United Therapeutics presented a pipeline of 14 products that the company says could generate long-term annual pharmaceutical sales of USD 50–100 billion. Near-term catalysts include approvals for Ralinepag (PDUFA date), Tyvaso variants for IPF/PPF and progress in xenotransplantation. Management announced an accelerated USD 500 million share repurchase program and raised the operating budget target for pipeline funding to 55% of last year’s revenue, but warned of execution risks in trials, manufacturing and high investment costs for xenotransplantation. » Mere på de.investing.com

I 2022 har United Therapeutics Co. allerede udloddet 0,47 € i udbytte. Den seneste udlodning fandt sted i maj 2022.

Virksomhedstal

I det seneste kvartal havde United Therapeutics Co. en omsætning på 734,97 mio. € og et nettoresultat på 228,31 mio. €
(EUR) september 2026
YoY
Omsætning 734,97 mio. 7,88 %
Bruttofortjeneste 647,48 mio. 8,77 %
Nettoresultat 228,31 mio. 20,90 %
EBITDA 325,24 mio. 17,55 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
22,87 mia. €
Antal aktier
42,59 mio.
Højeste/laveste i 52 uger
557,92 € - 413,86 €
Udbytte Nej
Beta
0,56
P/E (PE Ratio)
20,70
PEG (PEG Ratio)
118,03
K/I (PB Ratio)
4,02
P/S (PS Ratio)
7,90

Virksomhedsprofil

United Therapeutics Corporation er et bioteknologiselskab, der udvikler og kommercialiserer produkter til at imødekomme den udækkede medicinske behov hos patienter med kroniske og livstruende sygdomme i USA og internationalt. Selskabets kommercielle terapier omfatter Remodulin til behandling af patienter med pulmonal arteriel hypertension (PAH) for at mindske symptomer forbundet med motion; Tyvaso, en inhaleret formulering af prostacyclinanalogen treprostinil til at forbedre motionsevnen hos PAH-patienter og pulmonal hypertension forbundet med interstitiel lungesygdom (PH-ILD); Orenitram, en tabletform af treprostinil til at forbedre motionskapaciteten hos PAH-patienter; Unituxin, et monoklonalt antistof til behandling af højrisiko-neuroblastom; og Adcirca, en oral PDE-5-hæmmer til at forbedre motionsevnen hos PAH-patienter. Selskabet udvikler desuden Tyvaso DPI, en tør pulverinhalationsform af Tyvaso; Remunity Pump, en lille, let og holdbar pumpe med en separat controller; RemoPro og Ralinepag til behandling af PAH; Aurora-GT, et genterapiprodukt til at genopbygge blodkarrene i lungerne; og Tyvaso PERFECT- og TETON-studierne, som er undersøgelser af Tyvaso hos patienter med pulmonal hypertension i World Health Organization (WHO) gruppe 3 forbundet med kronisk obstruktiv lungesygdom (PH-COPD). Selskabet har licens- og samarbejdsaftaler med DEKA Research & Development Corp. om at udvikle et semi-engangssystem til subkutan levering af treprostinil; MannKind Corporation om at udvikle og licensere treprostinil-inhalationspulver og Dreamboat-enheden; og Arena Pharmaceuticals, Inc. om at udvikle Ralinepag. Selskabet blev stiftet i 1996 og har hovedkontor i Silver Spring, Maryland.

Navn
United Therapeutics Co.
CEO
Martine A. Rothblatt
Hjemsted Silver Spring, md
USA
Websted
Sektor
Sundhed
Branche
Bioteknologi
Børsnotering
17.06.1999
Medarbejdere 1.400

Tickersymboler

Børs Symbol
NASDAQ
UTHR
Frankfurt
UTH.F
Düsseldorf
UTH.DU
SIX
UTH.SW
München
UTH.MU
🍪

Parqet  bruger cookies. Læs mere